Why Are Atea Pharmaceuticals Shares Plunging Today?

  • Atea Pharmaceuticals Inc AVIR has reported data from the Phase 2 MOONSONG trial of AT-527 in the outpatient setting in patients with mild or moderate COVID-19.
  • Related: Atea Unveils Trial Amendments, New Data For COVID-19 Program.
  • The trial did not meet the primary endpoint of clear reduction in SARS-CoV-2 viral load in the overall population compared to placebo.
  • Approximately two-thirds of patients were low-risk with mild symptoms. 
  • However, in high-risk patients with underlying health conditions, a reduction of viral load of about 0.5 log10 at Day 7 was observed at 550 mg and 1,100 mg BID compared with placebo.
  • Based on AT-527 data and the evolving COVID-19 environment, Atea and its partner Roche Holdings AG RHHBY are assessing potential modifications to the Phase 3 MORNINGSKY trial.
  • Hence, the companies now anticipate Phase 3 MORNINGSKY data in the 2H of 2022 against 2H of 2021 expected earlier.
  • Atea will host a conference call today at 8:30 a.m. ET.
  • Price Action: AVIR shares plunged 70.10% higher at $12.10 premarket on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsShort IdeasHealth CareMoversTrading IdeasGeneralBriefsCOVID-19 CoronavirusPhase 2 Trialwhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!